MEP2108A - Kristalni sastav koji sadrži escitalopram - Google Patents

Kristalni sastav koji sadrži escitalopram

Info

Publication number
MEP2108A
MEP2108A MEP-21/08A MEP2108A MEP2108A ME P2108 A MEP2108 A ME P2108A ME P2108 A MEP2108 A ME P2108A ME P2108 A MEP2108 A ME P2108A
Authority
ME
Montenegro
Prior art keywords
composition containing
crystalline composition
containing escitalopram
escitalopram
crystalline particles
Prior art date
Application number
MEP-21/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Troels Volsgaard Christensen
Ken Liljegren
Michiel Elema
Lene Andresen
Shashank Mahashabde
Sebastian P Assenza
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP2108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MEP2108A publication Critical patent/MEP2108A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-21/08A 2001-07-31 2002-07-25 Kristalni sastav koji sadrži escitalopram MEP2108A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31
PCT/DK2002/000513 WO2003011278A1 (en) 2001-07-31 2002-07-25 Crystalline composition containing escitalopram

Publications (1)

Publication Number Publication Date
MEP2108A true MEP2108A (xx) 2010-02-10

Family

ID=8160647

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-21/08A MEP2108A (xx) 2001-07-31 2002-07-25 Kristalni sastav koji sadrži escitalopram

Country Status (39)

Country Link
US (3) US6916941B2 (sr)
EP (2) EP1522539B1 (sr)
JP (4) JP2005525993A (sr)
KR (1) KR20040028947A (sr)
CN (2) CN1311819C (sr)
AR (1) AR034898A1 (sr)
AT (2) ATE352546T1 (sr)
AU (1) AU2002355624B2 (sr)
BG (1) BG108571A (sr)
BR (1) BR0206164A (sr)
CA (1) CA2451915C (sr)
CO (1) CO5560540A2 (sr)
CY (1) CY1106413T1 (sr)
DE (2) DE60217932T2 (sr)
DK (2) DK1522539T3 (sr)
EA (1) EA006213B1 (sr)
EG (1) EG24206A (sr)
ES (2) ES2233842T3 (sr)
HR (2) HRP20031073A2 (sr)
HU (1) HUP0401946A2 (sr)
IL (2) IL159326A0 (sr)
IS (1) IS7077A (sr)
MA (1) MA27349A1 (sr)
ME (1) MEP2108A (sr)
MX (1) MXPA04000849A (sr)
MY (1) MY126238A (sr)
NO (1) NO328346B1 (sr)
NZ (1) NZ530157A (sr)
PE (1) PE20030304A1 (sr)
PL (1) PL366995A1 (sr)
PT (2) PT1522539E (sr)
RS (1) RS8304A (sr)
SI (1) SI1414435T1 (sr)
TN (1) TNSN04021A1 (sr)
TR (1) TR200400189T2 (sr)
UA (1) UA79930C2 (sr)
UY (1) UY27404A1 (sr)
WO (1) WO2003011278A1 (sr)
ZA (1) ZA200309684B (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1173431T4 (da) 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
PT1522539E (pt) 2001-07-31 2007-03-30 Lundbeck & Co As H Composição cristalina contendo escitalopram
TWI306846B (en) 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US20110196032A1 (en) * 2005-05-20 2011-08-11 Ashish Gogia Pharmaceutical Dosage Form of an Antidepressant
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
KR20070067173A (ko) * 2005-08-29 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이정점 입도 분포를 갖는 고체 미립자 타달라필
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
US8252336B2 (en) 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
CN106397248A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种lcz696结晶粉末及其制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
JP6423133B1 (ja) * 2017-04-10 2018-11-14 東和薬品株式会社 エスシタロプラム医薬組成物
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) * 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (sr) * 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
WO1996041633A1 (en) 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
SK283309B6 (sk) 1997-07-08 2003-05-02 H. Lundbeck A/S Spôsob výroby citalopramu a medziprodukty
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DK1042310T3 (da) * 1997-11-11 2002-12-02 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
ES2189502T3 (es) 1998-10-20 2003-07-01 Lundbeck & Co As H Metodo para la prevencion de citalopram.
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
DK1173431T4 (da) 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
PT1522539E (pt) * 2001-07-31 2007-03-30 Lundbeck & Co As H Composição cristalina contendo escitalopram

Also Published As

Publication number Publication date
US20080305164A1 (en) 2008-12-11
CN1660074A (zh) 2005-08-31
HRPK20080410B3 (en) 2009-09-30
DE60217932T2 (de) 2007-08-30
AR034898A1 (es) 2004-03-24
IS7077A (is) 2003-12-15
SI1414435T1 (en) 2005-06-30
MY126238A (en) 2006-09-29
JP5192568B2 (ja) 2013-05-08
US7420069B2 (en) 2008-09-02
DE60202615T2 (de) 2006-01-12
NO20040380L (no) 2004-01-28
JP2012211186A (ja) 2012-11-01
EP1414435B1 (en) 2005-01-12
HK1070000A1 (en) 2005-06-10
PL366995A1 (en) 2005-02-07
TR200400189T2 (tr) 2004-12-21
NZ530157A (en) 2007-06-29
ES2233842T3 (es) 2005-06-16
RS8304A (sr) 2006-12-15
ATE352546T1 (de) 2007-02-15
ES2280892T3 (es) 2007-09-16
AU2002355624B2 (en) 2006-02-02
BG108571A (en) 2005-02-28
JP2011195591A (ja) 2011-10-06
JP4971477B2 (ja) 2012-07-11
MA27349A1 (fr) 2005-06-01
UY27404A1 (es) 2003-02-28
US6916941B2 (en) 2005-07-12
WO2003011278A1 (en) 2003-02-13
EP1522539A1 (en) 2005-04-13
US20030212128A1 (en) 2003-11-13
DK1414435T3 (da) 2005-05-09
HUP0401946A2 (hu) 2005-01-28
PT1522539E (pt) 2007-03-30
PT1414435E (pt) 2005-05-31
DK1522539T3 (da) 2007-05-07
CY1106413T1 (el) 2011-10-12
JP5719811B2 (ja) 2015-05-20
EA200400243A1 (ru) 2004-06-24
HRP20031073A2 (en) 2004-04-30
BR0206164A (pt) 2003-10-28
EP1522539B1 (en) 2007-01-24
ZA200309684B (en) 2004-12-22
CO5560540A2 (es) 2005-09-30
DE60217932D1 (de) 2007-03-15
KR20040028947A (ko) 2004-04-03
TNSN04021A1 (en) 2006-06-01
IL159326A0 (en) 2004-06-01
JP2005525993A (ja) 2005-09-02
CN1536997A (zh) 2004-10-13
HRP20080410A2 (en) 2008-10-31
MXPA04000849A (es) 2004-05-14
UA79930C2 (en) 2007-08-10
EA006213B1 (ru) 2005-10-27
CA2451915A1 (en) 2003-02-13
JP2010150283A (ja) 2010-07-08
ATE286730T1 (de) 2005-01-15
EG24206A (en) 2008-10-21
EP1414435A1 (en) 2004-05-06
NO328346B1 (no) 2010-02-01
CA2451915C (en) 2010-09-21
CN1311819C (zh) 2007-04-25
DE60202615D1 (de) 2005-02-17
US20050147674A1 (en) 2005-07-07
PE20030304A1 (es) 2003-03-27
IL159326A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
MEP2108A (xx) Kristalni sastav koji sadrži escitalopram
EP0611081A3 (en) Cement compositions in fine particulate form.
AU2002303385A1 (en) High luminescence phosphor particles
GB9903938D0 (en) Cementitious compositions
WO2001098245A3 (en) Triphenyl compounds as interleukin-4 antagonists
AU2002363415A1 (en) Tightly agglomerated non-oxide particles and method for producing the same
HUP0500137A2 (en) Pyrrolidine-2-ones as factor xa inhibitors, process for producing them and pharmaceutical compositions containing the same
AU2002225369A1 (en) Photobase generators, curable compositions prepared by using the same and process of curing
IL161617A0 (en) Desmethyl and didesmethyl metabolites of citalopram, methods for the preparation thereof and pharmaceutical compositions containing the same
AU2002219180A1 (en) Clay composition
AP2000001837A0 (en) Pharmaceutical compositions containing micronized bicyclic drugs.
AU2003265265A1 (en) Process for coating ceramic particles and compositions formed from the same
AU2003273096A1 (en) Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
AU2003289165A1 (en) Calcium phosphate base particulate compound, process for producing the same and composition comprising the compound
AU2003234240A1 (en) Pharmaceutical composition containing lamotrigine particles of defined morphology
AU2003213402A1 (en) Powdery medicinal compositions for inhalation and process for producing the same
AU2001279193A1 (en) Methods and compositions for the construction and use of viral envelops as display particles
AU2002347996A1 (en) Powdered epoxy composition
AU2002223617A1 (en) Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
AU2002251138A1 (en) Solid composition containing solid particles comprising at least one part fibres
SG159504A1 (en) Crystalline composition containing escitalopram oxalate
HUP0402418A3 (en) Substituted 1,5-diaminopentan-3-ol compounds, process for producing them, pharmaceutical compositions containing them and use thereof
AU2002312092A1 (en) Manufacture of materials from graphite particles
HK1027044A (en) Composition comprising finely divided, crystalline particles of budesonide
GB9822368D0 (en) Compositions for the entrapment of airborne particles